Empowering Precision Diagnostics
Bringing ImmunoGuide ELISA technologies to Europe and beyond
Validated ELISA kits for therapeutic drug monitoring and anti-drug antibody detection, for clinical labs, research institutions, and biotech teams. For Research Use Only.
Featured ELISA kits
Drug-level and anti-drug antibody assays across TNF-alpha, VEGF, EGFR, HER2, and more.
ADALIMUMAB ELISA
Analyte: Adalimumab
View kitADALIMUMAB ELISA (MAB-BASED)
Analyte: Adalimumab
View kitAFLIBERCEPT ELISA
Analyte: Aflibercept
View kitANTIBODY TO ADALIMUMAB ELISA
Analyte: Adalimumab
View kitANTIBODY TO BEVACIZUMAB ELISA
Analyte: Bevacizumab
View kitANTIBODY TO CERTOLIZUMAB PEGOL ELISA
Analyte: Certolizumab Pegol
View kitFrom our journal
Background on ELISA methods, therapeutic drug monitoring, anti-drug antibodies, and assay validation.
Atypical Carry-Over in a Gyrolab ADA Assay: Lessons from a Rituximab Biosimilar Case Study
A published case study targeting MabionCD20, a rituximab biosimilar, identified wave-like signal fluctuations in Gyrolab-based ADA assays caused by neutralization buffer chemistry and fluorophore-induced isoelectric point shifts. The investigation offers transferable troubleshooting principles for any laboratory running Gyrolab-based immunogenicity programs, particularly around drug tolerance and repeatability.
What "Highly Similar" Actually Requires: Analytical Methods for mAb Biosimilar Characterization
Regulatory approval of mAb biosimilars now depends less on replicating clinical trial results and more on high-resolution analytical characterization. A 2026 BioDrugs review of successful US and EU dossiers maps the assay strategies that matter, while the FDA's September 2025 waiver of a clinical efficacy study for a ustekinumab biosimilar makes the principle concrete for immunoassay and TDM scientists.
Measuring the Pathogen, Not the Host: A High-Sensitivity ESAT-6 Blood Assay Distinguishes Active TB Across the Infection Spectrum
A high-sensitivity biosensor for circulating ESAT-6 protein, a direct secretory product of Mycobacterium tuberculosis, produced a stepwise quantitative signal across the full TB infection spectrum in a 217-patient cohort presented at ADLM 2026. Unlike IGRAs, which measure host immune response, this antigen-direct approach distinguished active disease from latent infection and uninfected contacts with an AUC of 0.976, as reported in conference coverage pending peer-reviewed publication. Full analytical validation and prospective clinical data remain outstanding.